Tech Company Financing Transactions
Asher Bio Funding Round
Asher Bio closed a $55 million Series C funding round on 4/17/2024. Investors included RA Capital Management, AstraZeneca and Boxer Capital.
Transaction Overview
Company Name
Announced On
4/17/2024
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to advance the clinical development of its lead program, AB248, a novel CD8+ T cell selective IL-2, generated by fusing a reduced potency IL-2 mutein to an anti-CD8ß antibody.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
650 Gateway Blvd. 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Craig Gibbs
Chief Operating Officer
Kyle Elrod
Chief Scientific Officer
Ivana Djuretic
Chief Technical Officer
Andrew Yeung
VP - Bus. Development
Sheldon Okada
VP - Regulatory Affairs
James Cross
Browse more venture capital transactions:
Prev: 4/17/2024: Jago venture capital transaction
Next: 4/17/2024: Claimscore venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs